Ipigrix (Ipidacrine Hydrochloride)

Ipidacrine hydrochloride reversibly blocks the enzyme acetylcholinesterase, which normally breaks down acetylcholine at synapses. By inhibiting this enzyme, the drug raises acetylcholine levels at neuromuscular junctions and in the gut, leading to stronger muscle contractions and faster intestinal movement without directly activating the receptors.

The specific dose of Ipigrix is individualized by the treating physician based on the patient’s condition, weight, renal and hepatic function, and response to therapy. Healthcare professionals determine the appropriate amount, frequency, and route of administration for each patient.

Safety data for ipidacrine hydrochloride in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Pregnant or nursing patients must discuss treatment options with their healthcare provider.

To request Ipigrix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ipigrix (ipidacrine) offers reversible inhibition of acetylcholinesterase with a relatively rapid onset when given by injection, which can be advantageous in acute settings such as postoperative ileus. Compared with oral agents like pyridostigmine, it provides more controlled plasma levels and avoids gastrointestinal absorption variability, but requires parenteral administration.

Ipigrix should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from moisture and direct sunlight, and avoid freezing. Follow any additional handling instructions provided on the label.

Ipigrix is supplied as an injectable solution for intramuscular or subcutaneous injection. The healthcare professional selects the appropriate route, injection site, and volume based on the prescribed dose. Proper aseptic technique and correct needle size are essential to ensure safe administration.

The most serious risks include cholinergic crisis, which can cause severe muscle weakness, respiratory failure, and bradycardia; anaphylactic reactions; and significant hypotension. Patients should be monitored closely for signs of excessive cholinergic activity, especially during dose titration.

Ipigrix is contraindicated in individuals with known hypersensitivity to ipidacrine or any component of the formulation, in patients with severe cholinergic hypersensitivity, and in those with uncontrolled asthma or severe cardiac conduction disorders. It should also be used with caution in patients with renal or hepatic impairment.